Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V Leiden

American Journal of Clinical Pathology

Volumn 129, Issue 3, 2008, Pages 494-499

  Taylor, Laura J ^a   Oster, Robert A ^a   Fritsma, George A ^a   Tichenor, Patricia H ^a   Reed, Cari E ^a   Eiland, Barbara M ^a   Hudson, Christine L ^a   Marques, Marisa B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Activated protein C resistance; Cost savings; Factor V Leiden

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5; PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE ASSAY; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; HEALTH CARE COST; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUTATION; POPULATION; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; ACTIVATED PROTEIN C RESISTANCE; BLOOD EXAMINATION; ECONOMICS; GENETIC PROCEDURES; GENETICS; MASS SCREENING; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

ACTIVATED PROTEIN C RESISTANCE; FACTOR V; FEMALE; GENETIC TECHNIQUES; HEMATOLOGIC TESTS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MUTATION; PREVALENCE; PROTEIN C; SENSITIVITY AND SPECIFICITY;

EID: 41649096127     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4370VLY9PBDDEWF6     Document Type: Article

References (19)

1. Hernandez J. Cost effectiveness of laboratory testing. Arch Pathol Lab Med. 2003;127:440-445.
2. Bodenheimer T. High and rising health care costs, part 2: technologic innovation. Ann Intern Med. 2005;142:932-937.
3. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
5. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
6. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1134.
7. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 1997;277:1305-1307.
8. Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet. 1997;73:334-336.
9. Mack R, Samaan P, Podolak I, et al. Prevalence of factor V Leiden in African-Americans. Res Commun Mol Pathol Pharmacol. 1998;99:339-343.
10. Austin H, Hooper WC, Dilley A, et al. The prevalence of two genetic traits related to venous thrombosis in whites and African-Americans. Thromb Res. 1997;86:409-415.
11. Dilley A, Austin H, Hooper WC, et al. Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol. 1998;147:30-35.
12. Dowling NF, Austin H, Dilley A, et al. The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study. J Thromb Haemost. 2003;1:80-87.
13. Goualt-Heilmann M, Leroy-Matheron C. Factor V Leiden- dependent APC resistance: improved sensitivity and specificity of the APC-resistance test by plasma dilution in factor V-depleted plasma [letter]. Thromb Res. 1996;82:281-283.
14. Tripodi A, Negri B, Bertina RM, et al. Screening for the FV:Q506 mutation: evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost. 1997;77:436-439.
15. Press RD, Bauer KA, Kujovich JL, et al. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002;126:1304-1318.
16. Ragland BD, Reed CE, Eiland BM, et al. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance. Am J Clin Pathol. 2003;119:66-71.
17. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
18. McDonald JM, Smith JA. Value-added laboratory medicine in an era of managed care. Clin Chem. 1995;41:1256-1262.
19. Laposata M. What many of us are doing or should be doing in clinical pathology: a list of the activities of the pathologist in the clinical laboratory. Am J Clin Pathol. 1996;106:571-573.